EpiCast Report: Sepsis and Septic Shock – Epidemiology Forecast to 2026

2017-08-01
Price :
Published : Aug-2017
No. of Pages : 61

EpiCast Report: Sepsis and Septic Shock – Epidemiology Forecast to 2026

Summary

Sepsis is a life-threatening complication arising from an infection, which occurs when the body’s response to the infection damages its own tissues and organs. Sepsis can lead to multiple organ failure and death, especially if it is not recognized early and treated promptly (Elfeky et al., 2017; Mayo Clinic, 2016). Anyone can develop sepsis; however, the condition is more common among children less than one year of age, older adults, and those with weakened immune systems (Elfeky et al., 2017; Mayo Clinic, 2016).

In men and women, among the 7MM in 2016, the US had the highest age-standardized diagnosed incidence of sepsis and Japan had the lowest. In the 5EU (France, Germany, Italy, Spain, UK), the age-standardized diagnosed incidence of sepsis in men ranged between 94.91 cases per 100,000 population in France and 174.05 cases per 100,000 population in the UK in 2016. The age-standardized diagnosed incidence of sepsis in women in the 5EU ranged between 36.76 cases per 100,000 population in France and 128.05 cases per 100,000 populations in the UK in 2016. Due to data scarcity, the crude diagnosed incidence of sepsis for Italy is considered to be same as that of Spain and therefore the calculated age-standardized diagnosed incidence rates are also similar in these markets.

Among the 7MM, in men and women in 2016, the US had the highest age-standardized diagnosed incidence of septic shock and Japan had the lowest. In the 5EU, the age-standardized diagnosed incidence of sepsis in men ranged between 29.55 cases per 100,000 population in Germany and 52.57 cases per 100,000 population in the UK in 2016. Similarly, the age-standardized diagnosed incidence of septic shock in women in the 5EU ranged between 11.56 cases per 100,000 population in France and 38.86 cases per 100,000 population in the UK in 2016. Due to data scarcity, the crude diagnosed incidence of septic shock for Italy is considered to be same as that of Spain and therefore, the calculated age-standardized diagnosed incidence rates are also similar in these markets.

The report “EpiCast Report: Sepsis and Septic Shock – Epidemiology Forecast to 2026”, provides an overview of the risk factors, comorbidities, and the global and historical trends for sepsis and septic shock in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed incident cases of sepsis and septic shock, segmented by sex and by age (for all ages).

In depth, this report provides the following –
– The sepsis and septic shock epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Scope

– The Sepsis and Septic Shock EpiCast Report provides an overview of the risk factors and global trends of sepsis and septic shock in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of sepsis and septic shock, segmented by age (for all ages) and sex. The sepsis and septic shock diagnosed incident cases are further segmented by causative agent and organ dysfunction. Additionally, GlobalData epidemiologists provide a forecast for the in-hospital mortality cases of sepsis and septic shock, segmented by age for both sexes.
– The sepsis and septic shock epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Sepsis and Septic Shock EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global sepsis and septic shock market.
– Quantify patient populations in the global sepsis and septic shock market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for sepsis and septic shock therapeutics in each of the markets covered.
– Understand the causative agent, organ dysfunction, and mortality of sepsis and septic shock.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Ambulatory Surgical Centers Market by Product (EHR, Practice Management, Telehealth, Healthcare Analytics, PHM, Supply Chain Management, RCM, Surgical planning, Quality Management), Specialty Type (Single, Multi-specialty) – Global Forecast to 2025

The Ambulatory Surgical Centers market is projected to reach USD 7.2 billion by 2025 from 2.1 billion in 2020 at a CAGR of 27.6% during the forecast period.There is a growing inclination across the globe towards the adoption of healthcare IT technologies due to the increasing need to deliver quality care to patients while curtailing escalating healthcare costs. These robust IT solutions are designed to streamline workflow in healthcare systems, reduce expenses, and facilitate compliance with stringent regulatory guidelines. By-products and services, the healthcare providers segment accounted for the largest share of the Ambulatory Surgical Centers market in 2018 Based on products and services, the Ambulatory Surgical Centers market is segmented into healthcare provider solutions, h......
$5650

Risk-based Monitoring Software Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) – Global Forecast to 2025

“Risk-based monitoring (RBM) software market is projected to grow at a CAGR of 13.3%.” The RBM software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3% during the forecast period. The RBM software market has witnessed various advancements in products and their approvals to meet the needs of the pharmaceutical research and development industry worldwide. Growth in the market can primarily be attributed to factors such as the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials “The Enterprise RBM Software segment to hold the largest market share in 2020.” Based on type, the RBM software market is segmented into Enterprise RB......
$5650

Veterinary Vaccines Market by Disease (Swine Pneumonia, Avian Influenza, Rabies, Coccidiosis, Brucellosis, Canine Distemper), Type (Poultry, Livestock, Aquaculture, Porcine, Canine), Technology (Inactivated, Toxoid, Recombinant) – Global Forecast to 2025

“The veterinary vaccines market is projected to grow at a CAGR of 7.2% during the forecast period (2020–2025).” The global veterinary vaccines market size is projected to reach USD 11.3 billion by 2025 from USD 8.0 billion in 2020, at a CAGR of 7.2%. The growth of this market is driven majorly by factors such as the initiatives by various government agencies and animal associations to maintain animal health, rising incidence of zoonotic diseases, growth in the companion animal population, and the rising demand for animal-derived food products are driving the growth of this market. On the other hand, the high storage cost of vaccines is restraining market growth. “By technology, the recombinant vaccines segment is expected to grow at the highest CAGR during the forecast period......
$4950

COVID-19 Impact on Vaccines & Drugs Market – Global Forecast to 2025

"The global COVID 19 vaccines market is projected to grow at a CAGR of -14.9% during the forecast period." The global COVID-19 vaccines market is projected to reach USD 1,401 million by 2025 from USD 2,273 million in 2022, at a CAGR of -14.9% during the forecast period. The growth of the global COVID-19 vaccines market is majorly attributed to the increasing number of people infected with COVID-19 and growing funding for vaccine development. "The global COVID 19 drugs market is projected to grow at a CAGR of -57.8% during the forecast period." The global COVID-19 drugs market is projected to reach USD 2 million by 2025 from USD 165 million in 2020, at a CAGR of -57.8% during the forecast period. The growth of COVID-19 drugs market is attributed primarily to use of repurposed drugs......
$5650

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides ......
$1000

CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2020 Edition

CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2020 Edition Summary This report is the 10th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. Scope This report is required reading for - - CMO executives who must have deep understanding of the injectables marketplace to make strategic planning and investment decisions. - Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management. - Private equity investors that need a deeper understanding of the market to identify and value pote......
$4995

Colorectal Cancer: Global Drug Forecast and Market Analysis to 2028

Colorectal Cancer: Global Drug Forecast and Market Analysis to 2028 Summary Colorectal cancer (CRC) occurs in the large intestine or large bowel. It is the third most common cancer globally and is one of the most common causes of cancer deaths in the world. Early stage CRC is commonly treated with surgery, while metastatic colorectal cancer (mCRC) treatment is dominated by fluorouracil chemotherapy regimens in combination with angiogenesis inhibitors, primarily Roche's Avastin, and epidermal growth factor receptor (EGFR) inhibitors. GlobalData valued the CRC market at $6.4B in 2018. This market is defined as sales of generic chemotherapy and major branded drugs commonly prescribed for CRC patients across the 8MM. GlobalData expects the market to increase to $8.1B in 2028 at a Compound A......
$10995

Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast

Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast Summary This report contains a summary of the analyst consensus forecasts available in the GlobalData Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Despite the rapid development of COVID-19 therapies being developed the majority of the COVID-19 pipeline is in early stage development so there are few forecasts available. Currently there are three drugs indicated for COVID-19 which have analyst consensus forecasts available. Scope This 27-page report gives important, expert insight you won't find in any other source. 7 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is require......
$495

Medical Marijuana: Consumers’ Perspectives in the US and UK

Medical Marijuana: Consumers' Perspectives in the US and UK Summary GlobalData's Medical Marijuana, Consumers' Perspectives report combines an extensive survey and analysis of patients' perspectives in the US and UK to provide an in-depth consumer-centered review of the medical marijuana market. Components of the report include an in-depth breakdown of the survey and its respondents, detailed analysis of consumers' concerns and opinions of medical and recreational marijuana, information from interviews with patients receiving treatment with medical marijuana in the US and UK, and an assessment of the impact of the COVID-19 pandemic on the medical marijuana space. The report evaluates trends across different age groups, health statuses, and other parameters to inform insightful compariso......
$7995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Russia

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Russia Summary GlobalData, the industry analysis specialist, has released its latest report: "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Russia". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Russia. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by Glo......
$1995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy